Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 19/20 | 0.50 |
| ▸ | HTR2B | P41595 | 18/20 | 0.50 |
| ▸ | HTR2A | P28223 | 12/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6677547 | 1.00 | HTR2C (0.50) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 | |
| SCHEMBL6680810 | 0.79 | HTR2C (0.51) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 | |
| SCHEMBL6680808 | 0.79 | HTR2C (0.51) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 | |
| SCHEMBL30529740 | 0.75 | MTNR1B (0.59) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 | |
| SCHEMBL17020523 | 0.75 | MTNR1B (0.59) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 | |
| SCHEMBL28417583 | 0.75 | MTNR1B (0.59) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 | |
| SCHEMBL15255143 | 0.75 | MTNR1B (0.59) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 | |
| SCHEMBL17269309 | 0.75 | MTNR1B (0.59) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 | |
| SCHEMBL6682129 | 0.75 | MTNR1B (0.59) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 | |
| SCHEMBL6681416 | 0.75 | MTNR1B (0.59) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2825538-B1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | BRISTOL MYERS SQUIBB CO (US) | 2016-06-01 | — | — | EP | disclosed |
| EP-2825538-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | Bristol-Myers Squibb Company (US) | 2015-01-21 | — | — | EP | disclosed |
| US-8765767-B2 | Positive allosteric modulators of mGluR2 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-07-01 | — | — | US | disclosed |
| WO-2013138687-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-09-19 | — | — | WO | disclosed |
| US-20130245042-A1 | Positive Allosteric Modulators of MGLUR2 | BRISTOL-MYERS SQUIBB COMPANY | 2013-09-19 | — | — | US | disclosed |
| EP-1027043-B1 | BENZODIOXOLE, BENZOFURAN, DIHYDROBENZOFURAN, AND BENZODIOXANE MELATONERGIC AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2004-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245042-A1 | Positive Allosteric Modulators of MGLUR2 | GRM2, GRM1, GRIN2C | HTR2C 57/4885HTR2B 171/4885HTR2A 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.